While obesity has been found to be a risk factor for several types of cancer, its use as a prognostic tool is unclear. The authors have reviewed literature interrogating the link between overweight status and obesity and cancer prognosis for five distinct solid organ malignancies: colon, breast, ovarian, lung, and renal. There appears to be a positive correlation between overnutrition and poor prognosis in breast and colon cancer. Similarly, there may well be a survival advantage for overweight or obese patients with newly diagnosed renal cell carcinoma and smoking-associated lung cancer. The relationship between ovarian cancer and obesity is less clear, as is the relationship between lung cancer in never/scant-smokers and obesity.
CeschiM, GutzwillerF, MochH, EichholzerM, Probst-HenschNM. Epidemiology and pathophysiology of obesity as cause of cancer. Swiss Med Weekly, 2007; 137:50–56.
5.
OkashaM, McCarronP, McEwenJ, SmithG. Body mass index in young adulthood and cancer mortality: A retrospective cohort study. J Epidemiol Comm Health, 2002; 56:780–784.
6.
U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2006 Incidence and Mortality Web-Based Report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2010. www.cdc.gov/uscs. 2010 July 25.
7.
SiegelEM, UlrichCM, PooleEM, HolmesRS, JacobsenPB, ShibataD. The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer Control, 2010; 17:52–57.
SinicropeFA, FosterNR, SargentDJ, O'ConnellMJ, RankinC. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res, 2010; 16:1884–1893.
10.
MarshallJL. Risk Assessment in Stage II colorectal cancer. Oncology, 2010; 24:9–13.
11.
MeyerhartJA, NiedzwieckiD, HollisD, SaltzLB, MayerRJ, NelsonH, WhittomR, HantelA, ThomasJ, FuchsCS. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with Stage III colon cancer: Findings from cancer and leukemia Group B 89803. J Clin Oncol, 2008; 26:4109–4115.
12.
MeyerhardtJA, CatalanoPJ, HallerDG, MayerRJ, Benson ALIII, MacdonaldJS, FuchsCS. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer, 2003; 98:484–495.
13.
PischonT, LahmannPH, BoeingH, FriedenreichC, NoratT, TjønnelandAet al.Body size and risk of colon and rectal cancer in the european prospective investigation into cancer and nutrition. J Natl Cancer Inst, 2006; 98:920–931.
14.
MeyerhardtJA, TepperJE, NiedzwieckiD, HollisDR, McCollumAD, BradyD, O'ConnellMJ, MayerRJ, CummingsB, WillettC, MacdonaldJS, BensonAB, FuchsCS. Impact of body mass index on outcomes and treatment-related toxicity in patients with Stage II and III rectal cancer: Findings from intergroup trial 0114. J Clin Oncol, 2004; 22:648–657.
15.
Centers for Disease Control and Prevention. 2006. Top Ten Cancers. United States Cancer Statistics, National Program of Cancer Registries. http://apps.nccd.cdc.gov/uscs/toptencancers.aspx. 2010 July 25.
GunterM, HooverD, YuH, Wassertheil-SmollerS, RohanT, MansonJet al.Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. JNCI, 2009; 101:48–60.
18.
HealyL, RyanA, RowleyS, BoyleT, ConnollyE, KennedyMet al.Obesity increases the risk of postmenopausal breast cancer and is associated with more advanced stage at presentation but no impact on survival. Breast J, 2010; 16:95–97.
19.
BastarracheaJ, HortobagyiG, SmithT, KauS, BuzdarA. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med, 1994; 120:18–25.
20.
TaoM, ShuX, RuanZ, GaoY, ZhengW. Association of overweight with breast cancer survival. Am J Epidemiol, 2006; 163:101–107.
21.
LittonJ, Gonzalez-AnguloA, WarnekeC, BuzdarA, KauS, BondyMet al.Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol, 2008; 26:4072–4077.
22.
KroenkeC, ChenW, RosnerB, HolmesM. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol, 2005; 23:1370–1378.
23.
NúñezN, PerkinsS, SmithN, BerriganD, BerendesD, VarticovskiLet al.Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer, 2008; 60:534–541.
24.
ImkampeA, BatesT. Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis. Breast J, 2010; 16:156–161.
25.
PierceJ, StefanickM, FlattS, NatarajanL, SternfeldB, MadlenskyLet al.Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesityw. J Clin Oncol, 2007; 25:2345–2351.
MatthewsKS, StraughnJMJr, KemperMK, HoskinsKE, WangW, RocconiRP. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol, 2009; 112:389–393.
28.
SkírnisdóttirI, SorbeB. Prognostic Impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer. Int J Gynecol Cancer, 2008; 18:345–351.
29.
BarrettSV, PaulJ, HayA, VaseyPA, KayeSB, GlasspoolRM. Scottish Gynaecological Cancer Trials Group. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol, 2008; 19:898–902.
30.
MünstedtK, WagnerM, KullmerU, HackethalA, FrankeFE. Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control, 2008; 19:909–916.
31.
LiA, ElmoreR, PavelkaJ, KarlanB. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol, 2007; 107:420–423.
YangL, YanG, ZhouM, SmithM, GeH, BorehamJ, HuY, PetoR, WangJ, ChenZ. Body mass index and mortality from lung cancer in smokers and nonsmokers: A nationally representative prospective study of 220,000 men in China. Int J Cancer, 2009; 125:2136–2143.
34.
SinghPN, LindstedKD. Body mass and 26-year risk of mortality from specific diseases among women who never smoked. Epidemiology, 1998; 9:246–254.
35.
KabatGC, MillerAB, RohanTE. Body mass index and lung cancer risk in women. Epidemiology, 2007; 18:607–612.
36.
KondoT, HoriY, YatsuyaH, TamakoshiK, ToyoshimaH, NishinoYet al.Lung cancer mortality and body mass index in a Japanese cohort: Findings from the Japan Collaborative Cohort Study (JACC Study)Cancer Causes Control, 2007; 18:229–234.
37.
KabatGC, KimM, HuntJR, ChlebowskiRT, RohanTE. Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol, 2008; 168:158–169.
38.
Centers for Disease Control and Prevention. 2006. Top Ten Cancers. United States Cancer Statistics, National Program of Cancer Registries. http://apps.nccd.cdc.gov/uscs/toptencancers.aspx. 2010 July 25.
39.
JeonHG, JeongIG, LeeJH, LeeCJ, KwakC, KimHH, LeeSE, LeeE. Prognostic value of body mass index in Korean patients with renal cell carcinoma. J Urol, 2010; 183:448–454.
40.
ParkerAS, LohseCM, ChevilleJC, ThielDD, LeibovichBC, BluteML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology, 2006; 68:741–746.
41.
KamatAM, ShockRP, NayaY, RosserCJ, SlatonJW, PistersLL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology, 2004; 63:46–50.
42.
SchraderAJ, RustemeierJ, RustemeierJC, TimmesfeldN, VargaZ, HegeleA, OlbertPJ, HofmannR. Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Epidemiol, 2009; 135:1693–1699.
43.
HaferkampA, PritschM, BedkeJ, WagenerN, PfitzenmaierJ, BuseS, HohenfellnerM. The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. Br J Urol Int, 2008; 101:1243–1246.
44.
DonatSM, SalzhauerEW, MitraN, YankeBV, SnyderME, RussoP. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J Urol, 2006; 175:46–52.
45.
AwakuraY, NakamuraE, ItoN, YamasakiT, KambaT, KamotoT, OgawaO. Influence of body mass index on prognosis of japanese patients with renal cell carcinoma. Urology, 2007; 70:50–54.
46.
SchipsL, LipskyK, ZigeunerR, GidaroS, SalfellnerM, RehakP, PummerK, HubmerG. Does overweight impact on the prognosis of patients with renal cell carcinoma? A Single Center Experience Of 683 Patients. J Surg Oncol, 2004; 88:57–61discussion, 61–62.
47.
PaisR, SilaghiH, SilaghiAC, RusuML, DumitrascuDL. Metabolic syndrome and risk of subsequent colorectal cancer. World of Gasteroenterol, 2009; 15:5141–5148.
48.
GonulluG, KahramanH, BedirA, BektasA, YucelI. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 2010; 25:205–212.
49.
BrennanAM, MantazorosCS. Metabolism: Drug insight: The role of leptin in human physiology and pathophysiology: Emerging clinical applications. Nature Rev Endocrinol, 2006; 2:318–327.
50.
WerynskaB, KosackaM, GoteckiM, JankowskaR. Leptin serum levels in cachetic and non-cachetic lung cancer patients. Pneumonol Alergolog Pols, 2009; 77:500–506.
51.
ConsidineRV, SinhaMK, HeimanML, KriauciunasA, StephensT, NyceM. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. NEJM, 1996; 334:292–295.
52.
StattinP, LukanovaA, BiessyC, SoderbergS, PalmqvistR, KaaksR, OlssonT, JellumE. Obesity and colon cancer: Does leptin provide a link?Int J Cancer, 2004; 109:149–152.
GoodwinP, EnnisM, FantusI, PritchardK, TrudeauM, KooJet al.Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?J Clin Oncol, 2005; 23:6037–6042.
55.
DaiQ, GaoY, ShuX, YangG, MilneG, CaiQ, WenW, RothmanN, CaiH, LiH, XiangY, ChowW, ZhengW. Oxidative stress, obesity, and breast cancer risk: Results from the Shanghai Women's Health Study. J Clin Oncol, 2009; 27:2482–2488.
56.
SatoT, TakedaH, OtakeS, YokozawaJ, NishiseS, FujishimaS, OriiTet al.Increased plasma levels of 8-Hydroxydeoxyguanosine are associated with development of colorectal tumors. J Clin Biochem Nutr, 2010; 47:59–63.
57.
KumarB, KoulS, KhandrikaL, MeachamRB, KoulHK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Research, 2008; 68:1777–1785.
58.
GuptaA, SrivastavaS, PrasadR, NatuSM, MittalB, NegiMPS, SrivastavaAN. Smoking intensity, oxidative stress and chemotherapy in non-small cell lung cancer: A correlated prognostic study. BioSci Trends, 2009; 3:191–199.
59.
PylväsM, PuistolaU, KauppilaS, SoiniY, KarihtalaP. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer, 2010; 46:1661–1667.
60.
BrownNS, BicknellR. Hypoxia and oxidative stress in breast cancer, oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res, 2001; 3:323–327.
61.
GascheC, ChangC, RheesJ, GoelA, BolandCR. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res, 2001; 61:7444–7448.
